---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-008904"
form_type: "8-K"
ticker: "LONA"
cik: "0001620463"
company_name: "LeonaBio, Inc."
filed_at: "2026-01-09T23:59:59+00:00"
generated_at: "2026-05-16T11:03:58.087357+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Athira Pharma renames to LeonaBio (LONA); lasofoxifene Phase 3 >50% enrolled; CFO gets new severance

## Summary
- Name change to LeonaBio effective Jan 9, 2026; ticker to LONA on Nasdaq starting Jan 12.
- Phase 3 ELAINE-3 trial of lasofoxifene >50% enrolled; topline data expected mid-2027.
- CFO Robert Renninger entered amended change in control severance agreement; base salary increased to $460,000.
- Name change reflects Dec 2025 acquisition of lasofoxifene rights, with $90M upfront financing and potential additional $146M.

## SEC filing metadata
- accession: 0001193125-26-008904
- form_type: 8-K
- ticker: LONA
- cik: 0001620463
- company_name: LeonaBio, Inc.
- filed_at: 2026-01-09T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.03, 7.01, 8.01, 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1620463/000119312526008904/0001193125-26-008904-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1620463/000119312526008904/atha-20260107.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-008904
- JSON: https://secwatch.observer/filing/0001193125-26-008904.json
- Plain text: https://secwatch.observer/filing/0001193125-26-008904.txt

## Source-grounded claims
- claim_id: 312235b1bf84c3e1e05e8ef2a22d0f7858c6b515
  claim: LeonaBio, Inc.: Certificate of Amendment to Amended and Restated Certificate of Incorporation to change corporate name from Athira Pharma, Inc. to LeonaBio, Inc (effective 2026-01-09).
  evidence_excerpt: Effective January 9, 2026, Athira Pharma, Inc. (the “Company”) changed its name to LeonaBio, Inc. (the “Name Change”). The Name Change was approved by the Company’s Board of Directors (the “Board”) and was effectuated through the filing of a Certificate of Amendment (the “Certificate of Amendment”) to the Company’s Amended and Restated Certificate of Incorporation with the Delaware Secretary of State.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1620463/000119312526008904/0001193125-26-008904-index.htm
- claim_id: 69eae61f6a6e9483c12cc498b59fe6d70dee29ad
  claim: LeonaBio, Inc.: Amended and restated bylaws to reflect the name change to LeonaBio, Inc (effective 2026-01-09).
  evidence_excerpt: Additionally, effective January 9, 2026, the Board approved an amendment and restatement of the Company’s bylaws (the “Amended and Restated Bylaws”) to reflect the Name Change.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1620463/000119312526008904/0001193125-26-008904-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.